Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real world effectiveness and use of prasugrel and other ADP receptor inhibitor therapies among myocardial infarction (MI) patients treated with percutaneous coronary intervention (PCI) during the index hospitalization. Patient management and treatment decisions are at the discretion of the care team per routine clinical practice. Approximately 17,000 patients will be enrolled at approximately 350 sites in the United States. Follow-up will be conducted through 15 months in approximately 15,650 patients.
TRANSLATE-ACS will complement the results of both randomized controlled clinical trials and current registries in addressing the real world treatment patterns and clinical outcomes for MI patients managed with PCI and initiated on ADP receptor inhibitor therapy. In addition to determining the effectiveness of prasugrel in comparison to other ADP receptor inhibitors, the study will also determine factors associated with initial ADP receptor inhibitor selection and longitudinal patterns of use, evaluate the safety, and describe and compare resource use and medical costs associated with ADP receptor inhibitors. Additionally, this study will generate a continuum of information from the inpatient to outpatient settings to provide a comprehensive picture of patient treatment and outcomes not currently available for novel ADP receptor inhibitors.
| Condition | Intervention |
|---|---|
|
Acute Coronary Syndrome |
Drug: ADP receptor inhibitors |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome |
- Major adverse cardiovascular events (MACE) [ Time Frame: 12 months ] [ Designated as safety issue: No ]MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization
- Factors associated with initial ADP receptor inhibitor selection at enrollment and longitudinal patterns of use [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Bleeding outcomes [ Time Frame: Index hospitalization, 1, 6, 12, 15 months ] [ Designated as safety issue: Yes ]
- MACE and bleeding outcomes in patients who have no prior history of transient ischemic attack (TIA)/stroke, weigh ≥60 kg, and are age <75 years old [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- MACE [ Time Frame: Index hospitalization, 1, 6, 15 months ] [ Designated as safety issue: No ]
- Stent thrombosis [ Time Frame: 15 months ] [ Designated as safety issue: No ]
- Resource use patterns, cumulative total medical costs, and cost effectiveness [ Time Frame: 15 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 17350 |
| Study Start Date: | March 2010 |
| Estimated Study Completion Date: | February 2014 |
| Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
ADP receptor inhibitor treatment
Patients admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
|
Drug: ADP receptor inhibitors
Dosage regimen as determined by the treating physician.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients admitted or already in hospital with acute myocardial infarction (MI) who are treated with percutaneous coronary intervention (PCI) and an ADP receptor inhibitor.
Inclusion Criteria:
- greater than or equal to 18 years of age
- diagnosed with NSTEMI or STEMI treated with a PCI during the index hospitalization
- initiated (or continued) on ADP receptor inhibitor therapy before discharge
- fully informed and are able to provide written consent for longitudinal follow-up and data collection
Exclusion Criteria:
- simultaneously participating in a research study that directs choice of either an investigational or approved ADP receptor inhibitor within the first 12 months after MI
Contacts and Locations
Show 186 Study Locations| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours EST) | Eli Lilly and Company |
More Information
No publications provided by Eli Lilly and Company
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT01088503 History of Changes |
| Other Study ID Numbers: | 12549, H7T-US-B007 |
| Study First Received: | March 15, 2010 |
| Last Updated: | April 5, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Acute Coronary Syndrome Myocardial Ischemia Heart Diseases Cardiovascular Diseases Angina Pectoris |
Vascular Diseases Chest Pain Pain Signs and Symptoms |
ClinicalTrials.gov processed this record on May 22, 2013